Pharma News

Assam based Association of Advanced Pharmacy Practitioners (AAPP) decides that they will not participate in the forthcoming World Pharmacist Day celebration programme on 25th September as a mark of resentment over the issue of not maintaining uniform standard of national eligibility in Pharmacy admission procedure.

A three-drug medication known as a polypill, developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in preventing secondary adverse cardiovascular events in people who have previously had a heart attack, reducing cardiovascular mortality by 33 percent in this patient population.  These are findings from the SECURE trial led by Valentin Fuster, MD, PhD, Director of Mount Sinai Heart and Physician-in-Chief of The Mount Sinai Hospital, and General Director of CNIC.

Bayer announced the start of a Phase III clinical development program OCEANIC to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor, as a potential new treatment in patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

To commemorate 25 years of existence of National Pharmaceutical Pricing Authority (NPPA), a programme will be organised at the Dr. Ambedkar International Centre, Janpath. Union Minister for Chemicals & Fertilizers and Health & Family Welfare Dr. Mansukh Mandaviya will grace the occasion as Chief Guest. MoS for Chemicals & Fertilizers and New & Renewable Energy will grace the occasion as Guest of Honour.

Novartis said its Scemblix was approved by the European Commission for adult patients with chronic myeloid leukemia (CML), offering a new treatment approach for patients with intolerance to other therapies, as reported by Reuters.

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments.

Bharat Biotech International Limited rotavirus oral vaccine Rotavac has been introduced by Nigeria to immunize its children from the life- threatening diarrhoeal disease that affects millions of children worldwide.

Nigeria currently accounts for 14 percent of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world. Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria.

Recently Government has revised guidelines for the production linked incentive (PLI) scheme for promoting domestic manufacturing of medical devices.

Moderna is filing patent infringement lawsuits against Pfizer and BioNTech in the United States District Court for the District of Massachusetts and the Regional Court of Dusseldorf in Germany. Moderna believes that Pfizer and BioNTech copied two key features of it patented technologies.

Local supply of a medicine used to prevent malaria across Africa received a boost recently, as the World Health Organization (WHO) issued a quality certification to the first African manufacturer of a key antimalarial drug used to prevent infection in pregnant women and children. Called pre- qualification, this certification will enable Kenyan manufacturer Universal Corporation Ltd (UCL) to support regional efforts to combat malaria through local production of high-quality sulfadoxine-pyrimethamine (SP).